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Introduction. Interstitial lung disease (ILD) is prevalent in patients with autoimmune rheumatic diseases 
(ARD), leads to significant morbidity and mortality and is poorly characterized in South Africa (SA). We 
undertook this study to describe the clinical, serological and radiological features of ILD associated with 
ARD in a tertiary referral hospital.  
 
Methods. A cross-sectional study of patients with ILD attending the rheumatology and respiratory 
outpatient clinics of Groote Schuur Hospital between October 2018 and September 2019. Clinical, 
serological and radiological features were documented. We compared features of 3 groups of patients: 
rheumatoid arthritis (RA), systemic sclerosis (SSc) and other autoimmune connective tissue diseases 
(OCTD) which included idiopathic inflammatory myopathies, mixed connective tissue disease, systemic 
lupus erythematosus, primary Sjogren’s syndrome and overlap syndromes. Factors associated with usual 
interstitial pneumonia (UIP) subtype were assessed.  
 
Results. Of 124 patients, 37 (29.8%) had RA, 32 (25,8%) SSc and 55 (44.4%) OCTD.  Most patients were 
female (86.3%), of mixed racial ancestry (75.0%), and the median (IQR) age was 55 (46-66).  Over one-
third were smokers, emphysema was diagnosed in 22.6%, and one-third had previous pulmonary 
tuberculosis (PTB) infection. Smoking, emphysema, and previous PTB were higher in RA group but the 
difference was not statistically significant.  All SSc patients and more than two-thirds of RA and OCTD 
patients had gastroesophageal reflux disease (GORD).  
Nonspecific interstitial pneumonia (NSIP) was the commonest pattern of ILD (63.7%), followed by usual 
interstitial pneumonia (UIP) (26.6%) and other patterns (9.7%). RA patients had similar frequencies of 
NSIP and UIP. Patients with RA were significantly older (median (IQR)) at ILD onset (62 (55-68) years), 
compared to SSc (49 (38-56)) and OCTD (42 (33-56)) (p < 0.001). Pulmonary function tests (PFTs) were 
significantly worse in SSc and OCTD groups. Regarding MTX exposure, 37.1% patients has MTX 
prescribed before ILD diagnosis, 33.9% continued, started or restarted after ILD diagnosis. No case of acute 
pneumonitis was documented.  Pulmonary function tests and high-resolution computer tomography 
severity correlated poorly, with PFTs underestimating the severity. In the analysis comparing patients with 
and without UIP, RA diagnosis (OR 3.8, 95% CI 1.5-9.5), older age (0R 1.1, 95% CI 1.0-1.1), COPD (OR 
3.2, 95% CI 1.4-8.0), longer ARD-ILD interval, and higher FVC (OR 1.0, 95% CI 1.0-1.1) were 
significantly associated with UIP.   
Conclusions: ILD was most commonly diagnosed in RA and SSc patients, with NSIP seen most frequently 
overall. Smoking, GORD, and PTB were frequent comorbidities. Amongst RA patients, we observed older 
age of onset and, interestingly, similar frequencies of NSIP and UIP patterns. The use of MTX was not 
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CHAPTER 1: INTRODUCTION 
 
1.1 Context 
The lung is a common site for complications of systemic autoimmune rheumatic diseases (ARD). Lung 
involvement in ARD can involve parenchyma (interstitial lung diseases), airway, pleura (pleurisy and 
pleural effusions, and the pulmonary vessels (pulmonary hypertension (PH) and diffuse alveolar 
haemorrhage) [1]. Interstitial lung disease (ILD)  and PH are the most common lung manifestations seen 
in the ARD [2]. This review focuses on ILD in the ARD. 
Interstitial lung diseases are a heterogeneous group of inflammatory lung parenchyma disorders that have 
common radiological, pathological and clinical manifestations [3]. They are characterized by inflammation 
or fibrosis arising in the interstitium of the lung [4]. In patients with ARD, ILD is fairly common and leads 
to significant morbidity and mortality [1]. For example, SSc-ILD patients have estimated median survival 
of 5 to 8 years after ILD diagnosis [5]. Additionally, ILD is often challenging to treat due to its progressive 
nature, variable presentation, unpredictable response to therapy, and lack of guidelines to assist clinicians 
[6,7]. There is a need to evaluate ILD in ARD patients in order to clarify predictive factors, subtypes and 
outcomes and optimum therapies [5].  
The ARD that are frequently complicated by ILD include (in order of descending frequency) systemic 
sclerosis (SSc), idiopathic inflammatory myopathies (IIM), rheumatoid arthritis (RA), mixed connective 
tissue disease (MCTD) and undifferentiated connective tissue disease (UCTD), systemic lupus 
erythematous (SLE) and primary Sjögren’s syndrome (pSS) [7].  
Of concern, ARD treatment may lead to or exacerbate ILD. Patients with ILD prescribed methotrexate 
(MTX) and/or leflunomide (LEF) have been reported to have a higher risk of developing acute pneumonitis 
[2,5,8]. Nevertheless, there is a growing evidence that treatment with conventional disease modifying 
antirheumatic drugs (DMARDs) such as MTX  and LEF can prevent or delay the onset of ILD, treat ILD 
and can be safely continued in patients with ILD diagnosis without increasing the risk of progression and/or 
exacerbation of ILD in patients with ARD [9-12]. 
 
 
ILD subtypes in ARD  
According to its pathologic and radiologic features, ILD in ARD is classified into 6 subtypes: nonspecific 
interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), organizing pneumonia (OP), 
lymphocytic interstitial pneumonia (LIP), diffuse alveolar damaged (DAD)/acute interstitial pneumonia 
(AIP), and rarely, desquamative interstitial pneumonia (DIP) (Table 1)[13,14]. Each subtype has different 
frequencies amongst the various ARDs, with varying prognosis and treatment choices. The most common 
subtypes in ARD are NSIP and UIP. Combined patterns are occasionally observed [2,7]. The combination 
of UIP and DAD in association with any ARD portends a poor prognosis. The estimated 5-year mortality 
of UIP in patients with ARD is 50% [13].   
 
Prevalence of ILD in ARD 
The published prevalence rate varies widely because of differences in study designs, populations and the 
way in which lung disease  is defined [5]. The prevalence and characteristics of ILD in various rheumatic 




Pathogenesis and risk factors for develop ILD in ARD 
The pathogenesis of ARD-ILD is not clearly understood. Unknown triggers cause inflammatory cells to 
invade interstitial and alveolar spaces leading to epithelial damage that cause recruitment and activation of 
fibroblasts and myofibroblasts. This inflammation leads to increased extracellular matrix proteins and 
fibrogenic cell population, causing scarring within the lung [5].  
Risk factors for the development and progression of ILD, have been identified based on demographic data, 
physiologic decline and radiography (Table 3). Older age at onset of ARD symptoms has been implicated 
as a risk factor in all diseases except in MCTD [1,2,4,5,15-18]. Disease duration at ILD onset differs 
depending on the ARD: ILD is associated with early disease in SSc, MCTD and IIM and with advanced 
disease in RA, SLE and pSS [1,2,4,5,15-20].  Smoking has been implicated in RA and pSS 
[1,2,4,5,15,16,19]. In RA, smoking-related increased citrullination of proteins within the lungs leads to ILD 
[21]. Male gender is a risk factor in all ARD [1,16,15,2,3,22,4,13,6,19,23]. Specific disease features such 
as gastro-oesophageal reflux disease (GORD) in SSc and MCTD have also been identified [4,6,3,22,24]. It 
has been consistently reported that oesophageal dilatation and the presence of a high degree of GORD is 
associated with more severe lung impairment and more rapid decline of pulmonary function values in SSc 
patients. However, until now, is not clear whether antacid treatment helps pulmonary functions preservation 
in ILD [1].  Specific auto-antibodies related to the different ARD (for example, anti-topoisomerase 1 
(Scl70), rheumatoid factor (RF), anti-citrullinated antibody (anti-CCP) and anti-tRNA synthetase 
antibodies (ARS) including anti-Jo1 antibody) are associated with ILD development[13,21,25-
29,22,30,31,15,4,32,33,24]. Silica exposure in gold miners is associated with the development of diffuse 
SSc, and with higher frequency of ILD [32].  
Clinical presentation and diagnosis of ILD in ARD 
Commonly, ILD presents with symptoms of progressive exertional dyspnoea, a persistent non-productive 
cough, bi-basal crackles on chest examination, diffuse bilateral infiltrates on chest radiographs (CXR) and 
restrictive lung patterns on pulmonary function tests (PFT) characterised by reduced total lung capacity and 
forced vital capacity (FVC) and impaired diffusion capacity for carbon monoxide (DLCO) [3,7,34].  
Plain CXR are not very sensitive for identifying ILD, and are normal in up to 10% of ILD patients [5]. 
Isolated use of PFT is also insensitive with a high rate of tests not showing any abnormalities even in severe 
disease and can be affected by co-morbidities including PH that causes a disproportionate decrease in 
DLCO, and COPD that causes pseudo-normalization of lung volumes.  
The 6-minute walk test (6MWT) is useful for determining functional capacity and degree of oxygen 
desaturation. However, it is confounded by non-pulmonary factors such as joint pain, weakness and 
anaemia and correlates weakly with FVC. It is a useful adjuvant to tracking overall functional status but 
cannot replace HRCT or PFT for ILD diagnosis or determination of severity [7,4]. Dyspnoea is also a 
symptom of PH (World Health Organisation group 1, 3 and 4 frequently seen in ARDs) and another non-
lung parenchyma causes of PH that are frequent in many ARD including SSc, SLE and MCTD. In these 
cases,  echocardiogram is recommended, with right heart catheterism when there is high suspicion of this 
complication [33]. 
Although pathologic evaluation of a lung biopsy specimen is the most sensitive technique and the gold 
standard for confirming the ILD and subtype, it is rarely used, as the histopathologic pattern and distribution 
of radiographic abnormalities observed on chest high resolution computed tomography (HRCT) can 
accurately predict and correlate with the histopathologic findings [7,2]. Therefore, HRCT has become the 
standard for evaluation of patients with suspected ILD both to determine disease subtype and to assess 
disease severity. Chest HRCT may reveal any combination of abnormalities in the lung parenchyma, 
including: inflammation, fibrosis and granulomas [3].  
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Combined, chest HRCT and PFT can be reliably used to diagnose and monitor ILD-ARD. They assist in 
assessing severity, determining the prognosis, gauging disease progression and measuring response to 
therapy [3,7].  
 
Grading ILD severity 
The severity of ILD is based on clinical assessment, degree of PFT restriction and impaired gas exchange 
together with histologic and radiographic features[7]. Scoring systems for HRCT have been shown to 
provide prognostic information and thresholds therapeutic intervention, especially in SSc [35,26]. Goh et 
al. proposed a simple staging system based on disease extension on HRCT and degree of FVC impairment 
(table 4).  This approach classifies the disease severity as “limited” or “extensive” which provides a more 
accurate prognostic score than can be achieved with any single index in isolation [35,13,7,33,20,16].  These 
simple criteria may be useful for other ILD-ARD. 
Disease progression 
Criteria for disease progression are % FVC decline ³ 10% or % FVC decline <10% and a decline of % 
DLCO ³ 15% [4]. 
 
   ___________________________________________________________________________
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Table 1: Histologic and radiographic features of main ILD subtypes adapted from Wallace et all [7], 
Hochberg [6] and Hellemon [36] 
ILD 
subtype 
Pathologic features  HRCT findings 
NSIP Uniform, homogeneous 
pattern with variable degrees 
of inflammation 
• Bilateral, symmetric, basilar, peripheral ground-
glass opacities 
• Traction bronchiectasis 
• Intra and interlobular septal thickening and 
consolidations can be seen 
• Subpleural sparing characteristic if seen 
 
UIP Fibrotic areas interposed 
with normal or near-normal 
lung; fibroblastic foci 
• Bilateral, basilar, subpleural fibrosis with 
volume loss and architectural distortion 
• Subpleural cysts (“honeycombing”) 
• Traction bronchiectasis and bronchiolectasis 
common 
LIP Extensive lymphocytic 
infiltration associated with 
peribronchial lymphoid 
follicles 
• Lower lobe predominant 
• Perivascular thin-walled cysts 
• Can have surrounding ground-glass or 
centrilobular nodules 
• Associated septal/bronchovascular thickening 
(interstitial thickening) common  
OP Inflammation in distal 
airways 
• Central ground-glass opacity surrounded by 
denser consolidation 
• Airspace consolidation, often bilateral, usually 
patchy but can be lobar 
• Alternatively, can be nodular 
• Subpleural and/or peribronchovascular 
distribution 
• Area of involvement can change over time 
DAD Hyaline membrane • Bilateral patchy ground-glass opacities with 
airspace consolidation 
DIP Excess number of 
pigmented macrophages 
diffusely filling the alveoli, 
with associated thickening 
of the septa secondary to the 




epithelial cells and sporadic 
eosinophils can also be seen 
over the course of alveolar 
septa 
• Bilateral diffuse ground-glass appearance, 
reticular opacities interposed with relatively 
normal lung zones, forming a mosaic 
attenuation  
• Usually symmetrical and frequently involving 
the basal parts of the lungs. 
• Most common in subpleural area  
• Often associated with irregular lines and 
traction bronchiectasis  
• Peripheral microcysts implying dilated 
bronchioles and alveolar ducts may be seen  
• Honeycomb appearance is not common.  
NSIP, nonspecific interstitial pneumonia; UIP, usual interstitial pneumonia; OP, organizing 
pneumonia; LIP, lymphocytic interstitial pneumonia; DAD, diffuse alveolar damage; DIP, 
desquamative interstitial pneumonia. 
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Table 2:  Estimated worldwide prevalence and characteristics of ILD [7,5,2,4,8,25,3,1,30,6,16,17,14,18]     
ARD 
type 
ILD prevalence Characteristics  
SSc  Clinically up to 90% 
Clinically significative in 8-27%  
NSIP >> UIP >> COP> 
LIP, DAD and 
granulomatous lung disease 
 
IIM  Up to 70 – 90% 
>70% when associated with anti-synthetase antibodies 
NSIP >> UIP > DAD and 
OP 
RA  4 – 68% 
Clinically evident in approximately 10% 
UIP > NSIP > OP, DAD, 
LIP, DIP 
 
MCTD  20 – 90%  NSIP >> UIP 
pSS  2 – 30%   
Clinically evident in 9 – 24%  
NSIP >> LIP, UIP > OP  
 
UCTD  Limited data  
47 – 78%  
NSIP >> UIP 
 
SLE  1 – 15% 
Clinically uncommon  
NSIP >> LIP and OP >>> 
UIP 
 
ARD, autoimmune rheumatic disease; ILD, interstitial lung disease; HRCT, high resolution computer tomography; 
SSc, systemic sclerosis; IIM, idiopathic inflammatory myopathy; ASS, anti-synthetase syndrome; RA, rheumatoid 
arthritis; MCTD, mixed connective tissue disease; pSS, primary Sjogren’s syndrome; UCTD, undifferentiated 








Risk factors  Poor prognostic factors or predictors of 
disease progression 
 
SSc Older age 
Male gender  
African American 
Silica exposure in gold mines 
Shorter disease duration 
Diffuse SSc 
GORD 
Abnormal NFC  
Nucleolar ANA (anti-Scl70, anti-PM/Scl, 
anti-Th/To and anti-U3RNP antibodies 
High CRP 
Presence of proteinuria 
 
Increased age 
Male gender  
African American ethnicity 
Shorter duration of scleroderma 
Concomitant PAH/ cardiac involvement 
Early decline or low baseline FVC (<70%) 
and DLCO (< 40%) 
Higher extent of disease on CT (>20%) 
Presence of honeycombing/ UIP pattern 
High titres of anti-Scl70 
Elevated serum KL-6 levels 
Increased alveolar epithelial permeability  
 










Acute and subacute presentation 
Concomitant PAH and MDA5 
Anti-Ro52 
Low initial FVC 
 
RA Older age (> 60) 
Male gender at middle age 
Smoking 
Longer disease duration 
Active joint disease 
Radiographic joint damage 
HLA-DRB1*502  





Rapid decline of PFT during follow-up 
Decline in FVC > 10% anytime  
UIP pattern 
Extensive disease on images 
Low DLCO % predictor at presentation 
MCTD Advanced age 
Male gender 
Early disease 
Oesophageal dilatation, oesophageal 
Motor dysfunction  
Fulfilment of all MCTD criteria sets 
Presence of SSc clinical features 
Worse baseline functional status 
High anti-RNP antibody, anti-Ro52 
antibody and no prior arthritis 
 
Male gender 
Absence of arthritis  
Presence of anti-Ro52 
Elevated anti-RNP titer 
 
SLE Older age at onset of SLE (> 50) 
Greater disease duration (>10y) 
Postpartum 
Scleroderma-like features (sclerodactyly, 
RP, and abnormal NFC), anti-(U1) RNP, 
and anti-Ro antibodies 
High levels of hsCRP 
Hypocomplementemia 
Presence of serum cryoglobulins 
LE cells in peripheral blood  
 
 




Risk factors Poor prognostic factors or predictors of 
disease progression 
pSS Older age 
Male gender 
Smoking 
Longer disease duration 
RP 
Oesophageal involvement 
Positive for ANA, RF, anti-La, anti-Ro 
Hypergammaglobulinemia 
Lymphopenia 
Older age  
Oesophageal involvement 
RA, rheumatoid arthritis; SSc, systemic sclerosis; IIM, idiopathic inflammatory myopathy; MCTD, 
mixed connective tissue disease; SLE, systemic lupus erythematous; pSS, Sjogren’s syndrome;  ASS: 
anti-synthetase syndrome; HLA: human leukocyte antigen; CRP: C-reactive protein; hsCRP: high 
sensitive C-reactive protein; PAH: Pulmonary arterial hypertension; NFC: Nailfold capillaroscopy; RP: 
Raynaud’s phenomenon 
Table 4: ILD simple staging system for systemic sclerosis (SSc) as proposed by Goh et al [35] 
Limited disease Minimal disease on HRCT (< 20%) 
      Or 
Indeterminate disease on HRCT (10-30%) 
      + 
FVC ³ 70% 
Extensive disease Severe disease on HRCT (> 20%) 
      Or 
Indeterminate disease on HRCT (10-30%) 
       + 
FVC < 70% 
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Introduction. Interstitial lung disease (ILD) in patients with autoimmune rheumatic diseases (ARD) is 
poorly characterized in South Africa. We describe the clinical, serological and radiological features of ILD 
associated with ARD in a tertiary referral hospital.  
Methods. A cross-sectional study of 124 patients attending rheumatology and respiratory outpatient clinics. 
We compared three groups of patients: rheumatoid arthritis (RA), systemic sclerosis (SSc) and other 
autoimmune connective tissue diseases (OCTD). Factors associated with usual interstitial pneumonia (UIP) 
were assessed.  
 
Results. Of 124 patients, 37 (29.8%) had RA, 32 (25,8%) SSc and 55 (44.4%) OCTD.  Most patients were 
female (86.3%), of mixed racial ancestry (75.0%), and the median (IQR) age was 55 (46-66 years).  Over 
one-third were smokers, emphysema was diagnosed in 22.6%, one-third had previous pulmonary 
tuberculosis (PTB) infection, and the majority (75.6%) had gastroesophageal reflux disease. Nonspecific 
interstitial pneumonia (NSIP) was the commonest ILD pattern (63.7%), followed by UIP (26.6%) and other 
patterns (9.7%). Patients with RA were older, had similar frequencies of NSIP and UIP, and had 
significantly better pulmonary function tests than the SSc and OCTD groups. No case of acute pneumonitis 
was documented in ILD-ARD patients treated with methotrexate (MTX).  
Conclusions: ILD was most commonly diagnosed in RA and SSc, with NSIP seen most frequently overall, 
with similar frequencies of NSIP and UIP patterns amongst RA patients. The use of MTX was not 




KEY POINTS  
• ILD was most commonly diagnosed in RA and SSc patients 
• NSIP and UIP frequencies were not different amongst South African RA patients  
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Interstitial lung diseases (ILD) are a heterogeneous group of inflammatory lung parenchyma disorders that 
have common radiological, pathological and clinical manifestations [1]. In patients with autoimmune 
rheumatic diseases (ARD), ILD is highly prevalent, leads to significant morbidity and mortality [2] and is  
difficult to treat due to its variable presentation, progression and response to therapy, with a relative lack 
of guidelines to assist clinicians [3,4].    
In ARD, ILD is classified according to pathologic and radiologic features  into six subtypes: nonspecific 
interstitial pneumonia (NSIP), usual interstitial pneumonia (UIP), organizing pneumonia (OP), 
lymphocytic interstitial pneumonia (LIP) and diffuse alveolar damaged (DAD)/acute interstitial pneumonia 
(AIP) and rarely desquamative interstitial pneumonia (DIP) [1,5,6]. Each subtype has different frequencies 
in the various ARDs, with distinct treatment and prognosis. The most common types are NSIP and UIP. 
The presence of UIP and DAD in association with any ARD type portends the worst prognosis, with a 5-
year mortality of about 50% [5].  
ILD prevalence differs between ARDs, in systemic sclerosis (SSc) 70-90% patients are diagnosed with 
ILD, in idiopathic inflammatory myopathies (IIM) 15-70%, in mixed connective tissue disease (MCTD) 
20-85%, in rheumatoid arthritis (RA) 4-68%, in primary Sjogren’s Syndrome (pSS) 10-30% and in 
systemic lupus erythematosus (SLE) 2-10% [4].  
Risk factors for the development and progression of ILD in ARD include older age, male sex, smoking,  
disease duration (early in SSc, MCTD and IIM, advanced in RA, SLE and pSS), silica exposure in SSc, 
gastroesophageal reflux disease (GORD) and the presence of autoantibodies including anti-topoisomerase 
1, rheumatoid factor (RF) and anti-tRNA synthetase antibodies such as anti-Jo1 antibodies [7,5,8-14]. It 
has been consistently reported that oesophageal dilatation and the presence of a high degree of GORD is 
associated with more severe lung impairment and more rapid decline of pulmonary function values in SSc 
patients. However, until now, is not clear whether antacid treatment helps pulmonary functions preservation 
in ILD [2]. 
To date there are no published studies from sub-Saharan Africa examining ILD in all ARDs. Most of the 
data related to ILD in ARD are based on studies done in patients with SSc. A recent retrospective study of 
SSc patients from South African (SA) showed an ILD prevalence of 40%, and the majority (63%) 
developed ILD within the first year of SSc diagnosis. Interstitial lung disease was the cause of death in 
44%, and was associated with gold mining exposure [14]. This study will describe the clinical, serological 
and radiological features of ILD-ARD and their associations in patients attending a tertiary referral hospital.  
 
Patients and Methods 
 
This cross-sectional study included patients with ARD-ILD attending a South African tertiary level state 
hospital. The University of Cape Town Faculty of Health Sciences Human Research Ethics Committee 
approved the study. Patients from the Rheumatology and Respiratory outpatient clinics seen between 
October 2018 and September 2019 were included if they met the following criteria: age ≥ 18 years, ARD 
diagnosed according to classification criteria for each disease, and ILD diagnosed on high resolution 
computerized tomography (HRCT) and pulmonary function tests (PFTs). Patients with non-parenchymal 
lung disease (including pleural disease, airway disease or tumors) were excluded.  
 
Clinical details, autoantibody status, PFTs, current and previous medications, and smoking status 
(ever/current at the time of ILD diagnosis) were collated. Plain chest radiographs (CXR) and HRCT images 
were reviewed by a rheumatologist (EP), pulmonologist (GC) and radiologist (QSH), and ILD was 
classified into subtypes. We defined severe ILD as FVC < 70%, adapted from the staging system proposed 
by Goh et al for SSc [15], and estimated the extent of involvement using qualitative assessment. Chronic 
obstructive pulmonary disease (COPD) was defined either by PFT or emphysema seen on HRCT images 
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[16]. COPD with ILD was differentiated for the purposes of this study by identifying concomitant areas of 
radiological emphysema (in a patient with a smoking history) as an alternative explanation for the finding 
of an obstructive and restrictive picture. Gastroesophageal reflux disease (GORD) was defined by reflux 
symptoms and/or barium swallow and/or a dilated esophagus on HRCT. 
 
Patients were divided in three groups: RA, SSc and “other” autoimmune connective tissue diseases (OCTD) 
which included 14 patients with IIM, 10 with MCTD, 10 with SLE, three with pSS and 16 patients with 
overlap syndrome (majority with overlap SLE and SSc).  
 
The ANOVA, Kruskal Wallis and Chi squared were used to test the associations depending on the 
distribution of data and type of variables. Cohen’s kappa coefficient for agreement was used to measure 
the assessment of extensive disease. Sporadically missing covariates data were managed using multiple 
imputation, only if the proportion of missing data was less than 50%. Factors associated with UIP were 
assessed by univariable and multivariate analyses. Analyses were performed with STATA 14.0 (Stata Corp 
LP, College Station, Tx, USA) and p-values ≤ 0.05 were considered significant. 
 
Results  
Of 124 patients with ILD-ARD, 37 (29.8%) had RA, 32 (25.8%) SSc (24 diffuse cutaneous and 8 limited 
cutaneous disease) and 55 (44.4%) OCTDs (Table 1).  Most patients were female (86.3%), of mixed racial 
ancestry (75.0) and the median time to develop ILD after ARD diagnosis was 2 years. The median (IQR) 
age at ARD symptom onset and ILD diagnosis were 45 (35-55 years) and 55 (46-66 years) respectively. 
Within three years of ARD diagnosis, two thirds of the SSc and OCTD patients and almost half of RA 
patients had developed ILD. Compared to the SSc and OCTD groups, RA patients were older at ARD 
diagnosis (p <0.001), had longer disease duration before onset of ILD (p=0.06) and were older at ILD 




Thirteen patients (10%) were asymptomatic and the ILD diagnosis was made based on images requested 
for other reasons (Table 2). The most frequent CXR abnormalities were reticular, reticulonodular or nodular 
infiltrates. Of note, five out of 124 (4.0%) had no parenchymal abnormalities on CXR, but HRCT revealed 
NSIP. The commonest pattern was NSIP, and in the RA group the frequency of NSIP and UIP was similar. 
Patients in the SSc and OCTD groups had worse PFTs with significantly lower forced vital capacity (FVC), 
and diffusion capacity for carbon monoxide (DLCO).  The percentage of patients with severe disease (FVC 
< 70%) was greater in SSc and OCTD groups (50.0% and 58.2%) in contrast with 32.4% of RA patients 
(p=0.05).  
 
Usual Interstitial Pneumonia  
To demonstrate the predictors associated with the most serious ILD patterns, UIP, we compared patients 
with and without UIP (Table 3).  As expected, RA was associated with UIP (OR 3.8, 95% CI 1.5-9.5). 
Other associated variables were age (0R 1.1, 95% CI 1.0-1.1), COPD (OR 3.2 (95% CI 1.4-8.0), age at ILD 
diagnosis, longer ARD-ILD intervals, and better FVC at ILD diagnosis (OR 1.0 (95% CI 1.0-1.1).  
Interestingly, the PFTs in the UIP group were better overall than the non-UIP group, particularly median 
(IQR) of percentage of FVC at UIP diagnosis was 79 vs 71 in non-UIP patients, with OR 1.6, (95% CI 0.8 
– 3.0) and p-value = 0.128. In the multivariate analysis (table 4), adjusting for ARD type, concomitant 
COPD, tobacco smoking and exposure time to MTX, COPD and MTX mean time exposure before 
ILD diagnosis remained significantly associated with UIP (OR 2.8, (95% CI 1.0 – 8.0) and 1.0 




A high prevalence of smoking (over 60%) and previous PTB (33.1%) was observed. A significant number 
of patients (22.6%) had COPD in addition to their ILD. There was no difference in the prevalence of 
smoking amongst all groups of ILD No patient was HIV positive. All SSc patients and more than two thirds 
of other patients had GORD. In the SSc group, eight (72.7%) patients had significant environmental/ 
occupational exposure, including gold-mining related silica exposure (two patients), organophosphates 
(one patient), biomass fuels (one patient), sand (two patients), cotton (one patients) and one patient with 
multiple exposures (printing fumes, spray paint and metal dust). 
Autoantibodies 
The majority (74.2%) of patients were antinuclear antibody positive, including 86.4% of RA patients. C 
including 80% of RA patients (Table 2). Regarding SSc, nine patients had positive anti-topoisomerase 
antibodies, and one patient had anticentromere antibodies. Eight of 14 IIM patients had anti Jo-1 antibodies. 
 
 
Methotrexate and leflunomide exposure 
Regarding methotrexate (MTX) exposure, 37.1% of patients were prescribed MTX before ILD diagnosis, 
and 33.9% continued, started or restarted after ILD diagnosis (59.5% of RA, 25.0% of SSc and 21.8% of 
patients with OCTD). No case of acute pneumonitis was documented, despite a mean (SD) follow-up of 
14.8 (29.1) months after ILD diagnosis. Regarding leflunomide, 2% of the patients were exposed before 
ILD diagnosis, and 6% after diagnosis.  
 
Discussion  
In this study of ILD in ARD, we described the clinical, serological and radiological features of ILD in 
ARDs. We have shown that ILD is most commonly diagnosed in RA and SSc, and overall, NSIP was seen 
most frequently. This is similar to reports elsewhere [4,7,5] where were described the ILD phenotypes and 
management in different ARDs.  
 
In the RA group, patients developed ARD at an median age 54 years compared to other groups, and also 
developed ILD later. This is described elsewhere [8,7,17-19], where were is reported that one of the risk 
factors to develop ILD in RA is age > 60 years. We found similar distribution of NSIP and UIP in RA, in 
contrast to other studies that reported higher frequency of UIP [5,4,7,17]. The UIP patients had better PFTs 
compared to other ILD subtypes, yet UIP is described as one of the most severe ILD patterns with poor 
response to treatment and poor outcomes [17,5,4,7,3,8]. This finding can be related to the higher mortality 
among patients with UIP pattern, implying that patients with worse PFTs may have already died at the time 
the study was conducted. The SSc and OCTD patients tended to have early onset of ILD, with the majority 
presenting with ILD within the first year of ARD symptoms onset. Pulmonary function tests in these groups 
tended to be more severe than the RA group, with lower DLCO scores in reflecting either worse lung 
disease or concomitant pulmonary hypertension.  
 
Smoking was highly prevalent in this cohort, particularly amongst RA patients. This is an area for 
intervention, given the evidence that smoking is a risk for ILD in ARD patients [2,7,8,17]. GORD was a 
frequent comorbidity in our ILD patients, particularly, as expected, in the SSc group, highlighting the 
importance of aggressive therapy of this problem since GORD in these patients is associated with more 
severe and quicker decline of pulmonary functions although is not clear whether antacid treatment helps 
pulmonary functions preservation in ILD  [20,21,9]. Almost a third of patients in all groups had a prior 
history of PTB, reflecting the high prevalence in TB in the general population of SA. This needs to be taken 
into account when offering immunosuppressant therapy for the ARD and ILD. Elsewhere, a history of TB 
and COPD has been identified as a risk factor for ILD, particularly amongst male smokers [22]. The role 
of isoniazid prophylaxis in ILD-ARD patients in a TB endemic area needs to be explored.  
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Around one third of the patients in this cohort were treated with MTX (more than half in RA group), either 
before or after ILD onset. This proportion was much higher amongst RA patients where 65.9% of the 
patients were exposed before ILD onset and 59.5% after ILD onset. No case of acute pneumonitis was 
observed in any patients of our ILD patients exposed to MTX - in total 7605 patient-years of exposure 
overall. One RA patient with ILD experienced exacerbation of ILD symptoms eight months after initiating 
leflunomide in combination with MTX and died of respiratory failure a few months later. Elsewhere, MTX 
or LEF have been associated with acute pneumonitis if prescribed to patients with ILD [7,17,18]. 
Nevertheless, there is a growing evidence that treatment with conventional disease modifying antirheumatic 
drugs such as MTX  and LEF can be used to prevent or delay the onset of ILD, treat ILD and can be safely 
continued  in patients with ILD diagnosis without increasing the risk of progression and/or exacerbation of 
ILD [23-26].  
Plain chest radiographs are not very sensitive for identifying ILD, and were  normal in 4% of our cohort 
and up to 10% of ILD patients elsewhere [17]. Some patients with HRCT-ILD had normal PFTs. and, PFT 
and HRCT severity correlated poorly, with PFTs underestimating the severity. 
We suggest routine ILD screening with HRCT, in all newly diagnosed ARD patients, especially patients 
with SSc and OCTD, where around 2/3 of the patients had developed ILD in the first 3 years of their ARD 
and bearing in mind that 10% of our cohort were asymptomatic. This screening should be repeated during 
the first three years after ARD symptoms onset as the majority of patients in this cohort developed ILD 
within this period.  
Limitations of this study include missing data (serology, environmental and/or occupational exposure 
history), but we did attempt to correct this through statistical imputation. In addition, we could not calculate 
the prevalence or risk factors for ILD in this population because this cross-sectional review focused only 
on patients with ILD. The extent of lung involvement on chest HRCT was made by qualitative assessment 
rather than by the recommended quantitative CT analysis. We did not have echocardiogram, right heart 
catheterisation or 6-minurte walk test data for the majority of patients. All subjects were seen at a tertiary 
referral centre, thus potentially introducing referral bias may decrease our ability to generalise these results 
to the larger ILD-ARD community. We have not yet collated the therapy and outcomes of our patients. 
These limitations will be addressed in a prospective case-controlled study.  
In conclusion, ILD was most commonly diagnosed in RA and SSc, with NSIP seen most frequently 
overall, with similar frequencies of NSIP and UIP patterns amongst RA patients. The use of MTX was 
not associated with the development of acute pneumonitis in patients with ILD. We believe that, when 
necessary, we can continue prescribing MTX to ILD patients. In addition, our findings call for aggressive 
treatment of GORD. Smoking cessation may be a valuable intervention in these patients. Prospective 
longitudinal studies that allow us to investigate risk factors for ILD, the response to and safety of 
immunosuppressive therapy, as well as the role of TB prophylaxis will inform future practical guidelines 
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Table 1. Demographic, clinical and serological characteristics of 124 patients with ILD-ARD 
 












Female, n (%) 107 (86.3) 31 (83.8) 27 (84.4) 49 (89.1) 0.719 
Age at ARD symptoms onset, 
years (median (IQR))  
45 (35-55)  54 (45-62) 42 (34-52) 40 (29-49) <0.001 
Ethnic background (self-
reported), n (%) 
• Mixed ancestry 
• Black 



















Ever Smoker, n (%) 75 (60.5)  28 (75.7) 17 (53.1) 30 (54.5) 0.078 
Current Smoker, n (%) 28 (22.6)  13 (35.1) 6 (18.8) 9(16.4) 0.090 
Past smoker, n (%) 47 (37.9)  15 (40.5) 11 (34.4) 21 (38.2) 0.869 
Previous pulmonary tuberculosis, 
n (%) 
41(33.1)  13 (35.1) 12 (37.5) 16 (26.1) 0.688 
Environmental or occupational 
exposure, n (%) 
21/35(60.0) 4/5 (80.0) 8/11 (72.7) 9/19 (47.4) 0.242 
GORD, n (%) 94 (75.8)  25 (67.6) 32 (100.0) 37 (67.3) 0.001 
COPD, n (%) 28 (22.6) 13 (35.1) 6 (18.7) 9 (16.4) 0.090 
HIV, n (%) 0 (0)  0 (0) 0 (0) 0 (0) - 
RF, n (%)  79 (63.7)*  36 (97.3) 12 (37.5) 31 (56.4) <0.001 
ACPA, n (%) 22/46 (47.8) 16/20 (80) 1/5 (20) 5/21 (23.8) 0.001 
ANA, n (%) 92 (74.2)* 32 (86.4) 20 (62.5) 40 (72.3) 0.072 
ATA, n (%) 12/45 (27.0)  - 9/27 (33.3) 3/18 (16.7) 0.215 
ACA, n (%) 3/37 (8.0) - 1/22 (4.5) 2/15 (13.3) 0.336 
Anti-Jo1, n (%) 8/17 (47.1) 0(0) 0/1 (0)  8/16 (50.0)  <0.001 
* Multiple imputation was performed. Abbreviations: OCTD: Other Connective Tissue Diseases
 ; 
RA: rheumatoid arthritis; SSc: systemic 
sclerosis; IQR: Interquartile range; GORD: gastroesophageal reflux, COPD: chronic obstructive pulmonary disease, HIV: human 
immunodeficiency virus, RF: rheumatoid factor; ANA: anti-nuclear antibody; ATA: anti-topoisomerase  antibody; anti-Jo1, anti-histidyl 
transfer RNA synthetase antibody; ACA: anti-centromere antibody; ever smoker, having positive smoking history either current or past; 










Table 2. Details of interstitial lung disease in 124 patients with ILD-ARD   
 
 All=124  RA        
n=37  
SSc        
n=32  
OCTD   
n=55  
p value 
Symptomatic at ILD Dx, n (%) 111 (89.5%) * 34 (91.9) 29 (90.6) 48 (87.3) 0.756 
Age at ILD symptoms onset, 
years (median (IQR)) 
49 (40-61) 62 (55-68) 49 (38-56) 42 (33-56) <0.001 




5 (1-13) 2 (0-7.5) 1 (0-4) 0.058 
ARD-ILD interval < 1y, n (%) 56 (45.2) 12 (32.4) 15 (46.9) 29 (52.7) 0.155 
ARD-ILD interval < 3y, n (%) 76 (61.3) 17 (45.9) 20 (62.5) 39 (70.9) 0.054 
Disease subtype, n (%) 
    NSIP 79 (63.7) 19 (51.3) 26 (81.2) 34 (61.8) <0.001 
    UIP 33 (26.6) 18 (48.6) 4 (12.5) 11 (20.0) 
    Othera 12 (9.7) 0 (0.0) 2(6.3) 10 (18.2) 
FVC at ILD Dx, absolute 
(liters), median (IQR) 
2.1 (1.8-2.4) * 2.1 (1.8-2.6) 2.1 (1.9-2.5) 2.1 (1.6-2.3) 0.217 
FVC at ILD Dx, (% expected), 
median (IQR) 
74 (60-85) * 83 (70-100) 71 (64-82) 68 (56-82) <0.001 
FVC ≤70%, n (%) 60 (48.4) * 12 (32.4) 16 (50.0) 32 (58.2) 0.052 
DLCO at ILD Dx, median 
(IQR) 
48 (38-54) * 51 (42-58) 50 (41-59) 44 (35-50) 0.020 
MTX before ILD onset, n (%) 46 (37.1) * 24 (65.9) 8 (25.0) 14 (25.5) <0.001 
MTX after ILD onset, n (%) 42 (33.9) * 22 (59.5) 8 (25.0) 12 (21.8) <0.001 
MTX exposure before ILD 
diagnosis (months, mean (SD)) 
21.7 (46.2) * 46.9 (63.1) 12.0 (35.3) 9.9 (29.2) <0.001 
MTX exposure after ILD 
diagnosis (months, mean (SD))  
14.8 (29.1) * 19.7 (33.2) 15.1 (34.4) 11.4 (22.3) 0.049 
LEF before, n (%) 2 (1.6) * 2 (5.4) 0 (0.0) 0 (0.0) 0.092 
LEF after, n (%) 7 (6) * 5 (13.5) 1 (3.1) 1 (1.8) 0.045 
LEF exposure after ILD 
diagnosis (months, mean (SD))  
0.4 (2.4) * 1.1 (4.2) 0 (0) 0.02 (0.1) 0.545 
a
 LIP, OP and acute pneumonitis. *Multiple imputation was performed. Abbreviations: OCTD: Other Connective Tissue Diseases RA: 
rheumatoid arthritis; SSc: systemic sclerosis; ILD: interstitial lung disease; ACTD: autoimmune connective tissue disease; IQR: 




Table 3. Comparison of ILD-ARD patients features with and without usual interstitial pneumonia  
 




OR (95% CI) a 
Diagnosis 
     RA, n (%) 18 (54.5) 19 (20.8) 3.8 (1.5-9.5) 
     SSc, n (%) 4 (12.1) 28 (30.8) 0.5 (0.1-1.9) 
     OCTD, n (%)b 11 (33.3) 44 (48.4) 1 
Female, n (%) 26 (78.8) 81 (89.0) 0.4 (0.2-1.3) 
Age, median (IQR) 67 (56-72) 50 (41-61) 1.1 (1.0-1.1) 
Age at ARD symptoms onset, years 
(median (IQR)) 
50 (38-56) 42 (34-52) 1.0 (0.9-1.1) 
Black ethnicity, n (%) 5 (15.1) 21 (23.1) 0.6 (0.2-1.7) 
Ever Smoker n (%) 25 (75.8) 50 (54.9) 1.6 (0.7-3.8) 
Concomitant COPD, n (%)   13 (39.4) 15 (16.5) 3.2 (1.4-8.0) 
Age at ILD symptoms onset, 
median (IQR) 
61 (53-67) 47 (38-57) 1.1 (1.0-1.1) 
Symptomatic at ILD Dx, n (%) 30 (90.9) 81 (89.0) 1.2 (0.3-4.8) 




1 (0-4) 1.0 (1.0-1.2) 
ARD-ILD interval < 1y (%), n (%) 7 (21.2) 49 (53.8) 0.2 (0.1-0.6) 
ARD-ILD interval < 3y (%), n (%)   12 (36.4) 64 (70.3) 0.2 (0.1-0.6) 
FVC at ILD Dx, percentage (%), 
median (IQR) 
79 (66-100) 71 (59-82) 1.6 (0.8-3.0) 
FVC < 70% (%), n (%)   13 (39.4) 47 (51.6) 0.6 (0.3-1.4) 
a
 Odds ratio were calculated by univariable logistic regression analysis. 
b 
IIM, Idiopathic Inflammatory 
Myopathy; MCTD, Mixed Connective Tissue Disease; SLE, Systemic Lupus Erythematous; pSS, primary 
Sjogren syndrome; and overlap syndromes. RA, Rheumatoid Arthritis; SSc, Systemic Sclerosis; OCTD, other 
connective tissue diseases; ACTD, autoimmune connective tissue disease; ILD, interstitial lung disease; COPD, 












Table 4. Multivariable analysis 
 
 
logistic UIP ib3.groups  COPDemphysema eversmoker MTXexposurebeforeILDonset  
 
Logistic regression                               Number of obs   =        123 
                                                  LR chi2(5)      =      24.60 
                                                  Prob > chi2     =     0.0002 
Log likelihood = -59.230934                       Pseudo R2       =     0.1720 
 
------------------------------------------------------------------------------- 
          UIP | Odds Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
--------------+---------------------------------------------------------------- 
       groups | 
           1  |   2.084064   1.098725     1.39   0.164     .7415745    5.856893 
           2  |   .5335737   .3503677    -0.96   0.339     .1473189    1.932548 
              | 
COPDemphysema |   2.835487    1.50458     1.96   0.050      1.00221    8.022254 
   eversmoker |   1.265954   .6821332     0.44   0.662     .4403169     3.63974 
MTXexposurebe |   1.012554   .0052492     2.41   0.016     1.002318    1.022894 
        _cons |   .1494756   .0704932    -4.03   0.000     .0593117    .3767036 
------------------------------------------------------------------------------- 
 
 
 
